ODHIN


Optimising Delivery of Healthcare Interventions (ODHIN) was an EU-wide project focusing on understanding how best to translate the results of clinical research into everyday primary health care.

Introduction

The EU-funded initiative ODHIN (Optimising Delivery of Healthcare Interventions) aimed to maximise the translation of clinical research results into routine practice. Researchers from across Europe conducted studies on identification and brief intervention (IBI) programmes in primary health care (PHC) to reduce hazardous and harmful alcohol consumption. Besides behavioural, organisational and financial aspects, the effectiveness and cost effects of IBI were evaluated.

About the research

Over a four year period, 2011-2014, a multidisciplinary team of over 50 scientists from 19 partner
institutions in nine European countries carried out research across seven work packages. This included:

  • Systematic reviews investigating the impact of different behavioural, organisational and financial strategies in changing provider behaviour were undertaken across a range of clinical lifestyle interventions.
  • A baseline measurement of services for managing hazardous drinking in PHC available in European countries was carried out.
  • A cluster randomised controlled trial was performed to test the incremental effect of a range of strategies to improve the delivery of screening and brief advice for HHAC in primary health settings.
  • An evidence-based database on effective and cost-effective IBI measures for use in PHC was developed.

The Sheffield Alcohol Research Group led on Work Package 3 which concentrated on modelling the impact of several screening and brief intervention (SBI) strategies in a number of EU countries. We worked closely with colleagues in The Netherlands, Italy and Poland to adapt the Sheffield Alcohol Policy Model to each of these countries to allow us to to evaluate the cost-effectiveness of SBI programs within different national contexts. The results of this work can be seen in the Cost-Effectiveness Model Report.

This work was supported by European Commission's Seventh Framework Program for research, technological development and demonstration [Grant agreement ID 259268]. The views expressed here reflect only the authors' and the European Commission is not liable for any use that may be made of the information contained therein.

Dates

January 2011 – December 2014

Funding

Total EU funding: €2,999,300.00
Funding to Sheffield: €413,387.00

Key contact

c.r.angus@sheffield.ac.uk

Papers

Angus C, Li J, Romero-Rodriguez E, Anderson P, Parrott S, Brennan A (2018) Cost-effectiveness of strategies to improve delivery of brief interventions for heavy drinking in primary care: results from the ODHIN trial European Journal of Public Health DOI: https://doi.org/10.1093/eurpub/cky181

Angus C, Thomas C, Anderson P, Meier PS, Brennan A. (2016) Estimating the cost-effectiveness of brief interventions for heavy drinking in primary health care across Europe European Journal of Public Health DOI: https://doi.org/10.1093/eurpub/ckw122

Angus C, Latimer N, Preston L, Li J, Purshouse R (2014) What are the implications for policy makers? A systematic review of the cost-effectiveness of screening and brief interventions for alcohol misuse in primary care Frontiers in Psychiatry DOI: https://doi.org/10.3389/fpsyt.2014.00114

Struzzo P, Angus C, Scafato E, Ghirini S, Torbica A, Ferre F, Scafuri F, Purshouse R, Brennan A (2014) Lo screening e l'intervento breve in medicina generale: un modello di analisi economica sui bevitori a rischio Politiche sanitarie DOI: http://dx.doi.org/10.1706/1567.17055

Angus C, Scafato E, Ghirini S, Torbica A, Ferre F, Struzzo P, Purshouse R, Brennan A (2014) Cost-effectiveness of a programme of screening and brief interventions for alcohol in primary care in Italy BMC Family Practice DOI: https://doi.org/10.1186/1471-2296-15-26

Reports

ODHIN Final summary report

Cost-Effectiveness – Model Report Deliverable D3.1, Work Package 3

Addendum to D3.1 Cost-effectiveness: analysis of the WP5 trial